Jason Bednar
Stock Analyst at Piper Sandler
(2.19)
# 2,891
Out of 5,090 analysts
190
Total ratings
40.97%
Success rate
-4.21%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Reiterates: Overweight | $83 → $94 | $81.40 | +15.48% | 15 | Dec 5, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $200 → $190 | $193.96 | -2.04% | 11 | Nov 7, 2025 | |
| ICUI ICU Medical | Maintains: Overweight | $153 → $172 | $142.51 | +20.69% | 3 | Nov 7, 2025 | |
| SOLV Solventum | Maintains: Overweight | $94 → $98 | $85.43 | +14.71% | 8 | Nov 7, 2025 | |
| SHC Sotera Health Company | Maintains: Neutral | $15 → $17 | $16.75 | +1.49% | 3 | Nov 5, 2025 | |
| MMSI Merit Medical Systems | Reiterates: Overweight | $105 → $109 | $83.43 | +30.65% | 14 | Oct 31, 2025 | |
| ALGN Align Technology | Reiterates: Overweight | $190 → $200 | $157.21 | +27.22% | 32 | Oct 30, 2025 | |
| MASI Masimo | Maintains: Overweight | $200 → $210 | $141.68 | +48.22% | 16 | Aug 6, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $19 | $20.23 | -6.08% | 13 | Aug 1, 2025 | |
| LUNG Pulmonx | Downgrades: Neutral | $9 → $2.5 | $2.01 | +24.38% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $12.11 | +180.76% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4.5 → $3.5 | $5.57 | -37.16% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $11.25 | +42.22% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $73.62 | +4.59% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $2.40 | +87.50% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $263.28 | +0.65% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $3.60 | +66.67% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $3.89 | +79.95% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $1.15 | +1,639.13% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $575.34 | -35.34% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $85.46 | +11.16% | 1 | Apr 19, 2023 |
The Cooper Companies
Dec 5, 2025
Reiterates: Overweight
Price Target: $83 → $94
Current: $81.40
Upside: +15.48%
Becton, Dickinson and Company
Nov 7, 2025
Maintains: Neutral
Price Target: $200 → $190
Current: $193.96
Upside: -2.04%
ICU Medical
Nov 7, 2025
Maintains: Overweight
Price Target: $153 → $172
Current: $142.51
Upside: +20.69%
Solventum
Nov 7, 2025
Maintains: Overweight
Price Target: $94 → $98
Current: $85.43
Upside: +14.71%
Sotera Health Company
Nov 5, 2025
Maintains: Neutral
Price Target: $15 → $17
Current: $16.75
Upside: +1.49%
Merit Medical Systems
Oct 31, 2025
Reiterates: Overweight
Price Target: $105 → $109
Current: $83.43
Upside: +30.65%
Align Technology
Oct 30, 2025
Reiterates: Overweight
Price Target: $190 → $200
Current: $157.21
Upside: +27.22%
Masimo
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $141.68
Upside: +48.22%
Envista Holdings
Aug 1, 2025
Maintains: Neutral
Price Target: $17 → $19
Current: $20.23
Upside: -6.08%
Pulmonx
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $2.01
Upside: +24.38%
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $12.11
Upside: +180.76%
May 8, 2025
Maintains: Neutral
Price Target: $4.5 → $3.5
Current: $5.57
Upside: -37.16%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $11.25
Upside: +42.22%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $73.62
Upside: +4.59%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.40
Upside: +87.50%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $263.28
Upside: +0.65%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $3.60
Upside: +66.67%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.89
Upside: +79.95%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $1.15
Upside: +1,639.13%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $575.34
Upside: -35.34%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $85.46
Upside: +11.16%